Premier Path Wealth Partners LLC Has $1.98 Million Stake in CVS Health Corporation (NYSE:CVS)

Premier Path Wealth Partners LLC raised its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 16.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,187 shares of the pharmacy operator's stock after acquiring an additional 4,025 shares during the quarter. Premier Path Wealth Partners LLC's holdings in CVS Health were worth $1,977,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Hopwood Financial Services Inc. bought a new position in CVS Health during the 4th quarter valued at $29,000. McIlrath & Eck LLC boosted its stake in CVS Health by 32.6% during the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after acquiring an additional 174 shares during the last quarter. MV Capital Management Inc. boosted its stake in CVS Health by 63.9% during the 1st quarter. MV Capital Management Inc. now owns 741 shares of the pharmacy operator's stock valued at $50,000 after acquiring an additional 289 shares during the last quarter. Dunhill Financial LLC boosted its holdings in shares of CVS Health by 147.2% in the 1st quarter. Dunhill Financial LLC now owns 749 shares of the pharmacy operator's stock valued at $51,000 after buying an additional 446 shares during the period. Finally, Financial Perspectives Inc raised its stake in CVS Health by 137.5% during the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock worth $36,000 after acquiring an additional 466 shares during the period. 80.66% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other CVS Health news, Director Guy P. Sansone purchased 1,570 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were purchased at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the transaction, the director now owns 12,007 shares in the company, valued at $764,845.90. This represents a 15.04% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.22% of the stock is currently owned by company insiders.

CVS Health Price Performance

Shares of NYSE CVS traded down $0.15 during mid-day trading on Friday, reaching $66.69. 11,828,346 shares of the company traded hands, compared to its average volume of 10,963,289. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $72.51. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63. The firm has a market cap of $84.36 billion, a PE ratio of 15.92, a price-to-earnings-growth ratio of 0.96 and a beta of 0.56. The stock has a fifty day simple moving average of $64.98 and a 200-day simple moving average of $60.35.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The business had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. During the same quarter last year, the business earned $1.31 earnings per share. The business's revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CVS. Piper Sandler raised their target price on shares of CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a report on Friday, March 21st. Barclays set a $79.00 target price on shares of CVS Health and gave the stock an "overweight" rating in a report on Monday, June 2nd. Royal Bank Of Canada raised their target price on shares of CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a report on Monday, May 5th. Wall Street Zen raised shares of CVS Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Finally, UBS Group raised their target price on shares of CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, CVS Health presently has an average rating of "Moderate Buy" and an average target price of $74.75.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.